Page 20 - PD-L1 EbookV2 Flip PDF
P. 20
Conclusion
A suboptimal PD-L1 diagnostic marketplace is already resulting in lost treatment
opportunities. As the dependence upon PD-L1 testing grows over the years and across
indications, this is highly likely to magnify.
The Diaceutics model suggests that up to $744 million in lost treatment revenue is at stake
in this one indication alone.
Based on this indication, an investment in optimizing the PD-L1 diagnostic marketplace is
likely to confer more than $20 additional therapy revenue for every $1 spent on diagnostic
investment. Improved quality of testing will deliver the greatest dollar for dollar return and
linking higher dosing to high PD-L1 expressing patients should see the single highest dollar
amount return.
Pharma asset and management teams are always concerned about the ‘opaque impact’ of
investing in diagnostic optimization. By employing real time tracking of the PD-L1 market
and reporting this in ‘lost treatment dollars’ it is our intention to highlight the significant
financial benefit of earlier and better planning in diagnostic market optimization.
Originally published at Diaceutics.com, 4 April 2016
Page 20 of 31
